This early-stage study is testing the safety of a new two-part cell therapy (SYNCAR-001 + STK-009) in adults with severe forms of lupus or scleroderma that haven't responded to other treatments. The therapy involves collecting and modifying a patient's own immune cells (CAR-T cel…
Phase: PHASE1 • Sponsor: Synthekine • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC